Raymond James analyst Andrew Cooper upgraded Haemonetics (HAE) to Strong Buy from Outperform with an unchanged price target of $120. The firm says that despite the 11% rally to the company’s fiscal Q2 results, it has increased conviction that the core business can sustain double-digit earnings growth and that the market continues to underappreciate Haemonetics’ assets. The Q2 report showed “the sky isn’t falling in vascular closure,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics’ Q2 2025 Earnings Show Strong Growth
- Haemonetics backs FY25 adjusted EPS view $4.45-$4.75, consensus $4.59
- Haemonetics reports Q2 adjusted EPS $1.12, consensus $1.07
- HAE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Moderna, Halliburton downgraded: Wall Street’s top analyst calls